DISTANCE FROM THE TOP:
initial

Selected Publications

  • Redner RL, Beumer JH, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Kropf P, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE. A Phase I study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia and Lymphoma, 2018. In Press.
  • Brand TM, Hartmann S, Bhola NE, Li H, Zang Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Res. 2018 Feb 12.
  • Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signaling axis in cancer. Nature Reviews Clinical Oncology Feb 6. doi: 10.1038/nrclinonc.2018.8. 2018 [Epub ahead of print]. (PMID: 29405201)
  • Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083.
  • Guo T, Sakai A, Afsari B, Considine M, Danilova L Favorov AV, Yegnasubramanian S, Kelley D, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, and Califano J. Definition of alternative splice expression in human papillomavirus-related oropharyngeal cancer includes a novel functional splice variant of AKT3. Cancer Research. 2017 Oct 1;77(19):5248-5258. Jul 21 [Epub ahead of print].
  • Johnson DE, Bauman JE. When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials. Cancer Prevention Research (Phila). 2017 Sep; 10(9):489-490.
  • Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research (Phila). 2016 Jul; 9(7):547-57.
  • Kang H, Tan M, Bishop JA, Jones S, Sausen M, Ha PK, Agrawal N. Whole exome sequencing of salivary gland mucoepidermoid carcinoma. Clin Cancer Res. 2017 jan 1;23(1):283-288. Epub 2016 Jun 23.
  • Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Aug; 9(8):657-63.
  • Ling S, Rettig EM, Tan M, Chang X, Wang Z, Brait M, Bishop JA, Fertig EJ, Considine M, Wick MJ, Ha PK. Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. Int J Oncol. 2016 Jul; 49(1); 225-34. Epub May 18.
  • Rettig EM, Talbot C, Sausen M, Jones S, Bishop JA, Wood LD, Tokheim C, Niknafs N, Karchin R, Fertig E, Wheelan S, Marchionni L, Considine M, Fakhry C, Papadopoulos N, Kinzler KW, Vogelstein B*, Ha PK*, Agrawal N*. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev Res (Phila). 2016 Apr;9(4)265-74. Epub Feb 9. *co-corresponding authors
  • Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. 2016 Mar 03; 35(9):1163-9.
  • Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016 Jan; 126(1):169-80.
  • Rettig EM, Tan M, Ling S, Yonescu R, Bishop J, Fakhry C, Ha PK. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. Laryngoscope, 2015 Sep; 125(9): E292-9.
  • Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44.
  • Wang Z, Ling S, Rettig E, Sobel R, Tan M, Fertig EJ, Considine M, El-Naggar AK, Brait M, Fakhry C, Ha PK. Epigenetic screening of salivary gland mucoepidermoid carcinoma identifies hypomethylation of CLIC3 as a common alteration. Oral Oncology, 2015 Dec;51(12):1120-5. Epub 2015 Oct 15.
  • Rettig EM, Tan M, Ling S, Yonescu R, Bishop J, Fakhry C, Ha PK. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. Laryngoscope, 2015 Sep; 125(9): E292-9.
  • Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Molecular Oncology. 2014 Oct; 8(7):1220-30.
  • Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1114-9.
  • Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncology 2014 Feb; 50(2):120-7.
  • Zang Y, Kirk CJ, and Johnson DE. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biology and Therapy 2014; 15(9):1142-1152.
  • Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul; 3(7):761-9.
  • Li C and Johnson DE. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle 2013; 12:923-934.
  • Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical Cancer Research 2012 Oct 15; 18(20):5639-49.
  • Shao C, Tan M, Bishop JA, Liu J, Bai W, Gaykalova DA, Ogawa T, Vikani AR, Agrawal Y, Li RJ, Kim MS, Westra WH, Sidransky D, Califano JA, Ha PK. Suprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma. PLoS One, 2012;7(11):e48582. Epub 2012 Nov 12.
  • Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012 Aug; 2(8):694-705.
  • Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012 Dec; 8(12):1873-4
  • Li C and Johnson DE. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Letters 2012; 314:102-107.
  • Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
  • Shao C, Sun W, Tan M, Glazer CA, Bhan S, Zhong X, Fakhry C, Sharma R, Westra WH, Hoque MO, Moskaluk CA, Sidransky D, Califano JA, and Ha PK. Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clinical Cancer Research. 2011 Jul 1;17(13):4320-30. Epub 2011 May 6.
  • Shao C, Bai W, Junn JC, Uemura M, Hennessey PT, Zaboli D, Sidransky D, Califano JA, and Ha PK. Evaluation of Myb promoter methylation in salivary adenoid cystic carcinoma. Oral Oncol. 2011 Apr;47(4):251-5. Epub 2011 Feb 15.
  • Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011 Feb; 4(2):230-7.
  • Durr ML, Mydlarz WK, Shao C, Zahurak M, Chuang AY, Hoque MO, Westra WH, Liegeois NJ, Califano JA, Sidransky D, and Ha PK. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One. 2010 May 26;5(5):e10828.
  • Kropf PL, Wang L, Zang Y, Redner RL, and Johnson DE. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia 2010; 24:663-665.
  • Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol. 2009 Mar 10; 27(8):1235-42.
  • Jones JE, Wang L, Kropf PL, Duan R, and Johnson DE. Src family kinase gene targets during myeloid differentiation: Identification of the EGR-1 gene as a direct target. Leukemia 2009; 23:1933-1935.
  • Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Molecular Pharmacology 2009 May; 75(5):1231-9.
  • Mithani SK, Shao C, Tan M, Smith IM, Califano JA, El-Naggar AK, and Ha PK. Mitochondrial mutations in adenoid cystic carcinomas of the salivary glands. PLoS One, 2009;4(12);e8493.
  • Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics 2009 Aug; 8(8):2211-20.
  • Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A. 2006 May 02; 103(18):6901-6.
  • Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005 Feb 03; 24(6):970-9.
  • Ha PK, Benoit NE, Westra WH, Sciubba JJ, Califano JA. A transcriptional progression model for head and neck cancer using expression microarrays. Clin Cancer Res. 2003 Aug 1;9(8):3058-64.
  • Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003 Apr 01; 100(7):4138-43.
  • Ha PK, Pai SI, Westra WH, Gillison ML, Tong BC, Sidransky D, Califano JA. Real time quantitative PCR demonstrates low prevalence of human papillomavirus Type 16 in Premalignant and Malignant Lesions of the Oral Cavity. Clinical Cancer Research. 2002 May; 8(5): 1203-9.